Lifecore Biomedical, Inc.

NASDAQ:LFCR

Drug Manufacturers - Specialty & Generic

Healthcare
$6.40 +0.27%

+$0.02 today

Market cap
$242.60M
Beta
1.07
P/E (TTM)
-6.1
EPS (TTM)
-$0.91
52W Low $3.63High $8.98

Volume 0.15M

Average 0.29M

LFCR Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Lifecore Biomedical, Inc.NASDAQ: LFCR

Gross Margin · Q3 FY2026 · quarter ended Mar 2026

Gross margin at 19.2%

Gross margin was 19.2% in Q3 FY2026. On a trailing-twelve-month basis it was 31.2%. Over 3 fiscal years it narrowed by 3.8 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
19.2%-16.6 pp QoQ
Last fiscal yearMay 2025
31.3%-1.4 pp YoY
LTMMar 2026
31.2%— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year-1.4 pp——
3 years-3.8 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
31.3%
Year-over-year change
-1.4pp

Gross Margin vs competitors

How LFCR compares with its peers on the latest reported figures

  • LFCR's LTM Mar 2026 gross margin of 31.2% is the 7th highest of the 9 companies compared; the peer median is 71.1%.
  • Over three fiscal years its change of -3.8 pp compares with a peer median of -1.4 pp.
LFCR Competitors Peer median
Gross Margin for LFCR and competitors
Company Period LTM level YoY 3-year change
BIOABioAge Labs, Inc.LTM Mar 202699.4% -0.6 pp—
PRQRProQR Therapeutics N.V.LTM Mar 202689.7% -10.3 pp-17.0 pp
SGHTSight Sciences, Inc.LTM Mar 202686.2% +0.5 pp+3.5 pp
CVRXCVRx, Inc.LTM Mar 202685.5% +1.8 pp+7.6 pp
ACBAurora Cannabis Inc.LTM Mar 202656.6% +2.0 pp-1.4 pp
TKNOAlpha Teknova, Inc.LTM Mar 202633.3% +12.3 pp-9.0 pp
LFCRLifecore Biomedical, Inc.LTM Mar 202631.2% —-3.8 pp
CGCCanopy Growth CorporationLTM Mar 202624.9% -4.7 pp+39.2 pp
IMMPImmutep LimitedFY2025-1117.6% -136.1 pp-6.4 pp
ACHVAchieve Life Sciences, Inc.FY2025— ——
Peer median (excluding LFCR) 71.1%-0.1 pp-1.4 pp

Competitors are the stored peer set for LFCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
May 2021
FY2022
May 2022
FY2023
May 2023
FY2024
May 2024
FY2025
May 2025
Revenue100.87M111.27M103.27M128.26M128.87M
Cost of Revenue61.94M72.2M75.28M86.41M88.57M
Gross Profit38.94M39.07M27.99M41.85M40.3M
Gross Margin38.6%35.1%27.1%32.6%31.3%
Research & Development6.68M7.84M8.74M8.58M8.26M
Selling, General & Admin27.72M34.66M38.97M40.46M44.05M
Operating Expenses47.76M50.86M49.78M50.69M57.54M
Depreciation & Amortization19.87M18.06M13.18M8M8.03M
EBITDA(987K)12.84M(33.17M)35.6M(8.81M)
EBITDA Margin-1.0%11.5%-32.1%27.8%-6.8%
Operating Income(8.82M)(11.79M)(21.8M)(8.84M)(17.25M)
Operating Margin-8.7%-10.6%-21.1%-6.9%-13.4%
Interest Income48K81K68K00
Interest Expense8.93M15.55M17.65M18.09M21.84M
Other Income / Expenses(20.96M)(8.9M)(42.13M)18.36M(21.43M)
Income Before Tax(29.79M)(20.69M)(63.93M)9.51M(38.67M)
Pre-Tax Margin-29.5%-18.6%-61.9%7.4%-30.0%
Income Tax Expense(6.35M)(5.21M)308K183K43K
Net Income(32.29M)(116.72M)(99.56M)12.01M(38.72M)
Net Margin-32.0%-104.9%-96.4%9.4%-30.0%
EPS (Basic)(1.12)(3.97)(3.32)0.39(1.27)
EPS (Diluted)(1.12)(3.97)(3.32)0.33(1.27)
Weighted Avg Shares29.29M29.47M29.96M30.47M34.82M
Weighted Avg Shares (Diluted)29.29M29.47M29.96M36.66M34.82M

Lifecore Biomedical, Inc.

NASDAQ:LFCR

Intrinsic Alpha fair value

Locked

Current Price

$6.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.